Publication

Article

Pharmacy Times

May 2019 Skin & Eye Health
Volume85
Issue 5

Generic Products (May 2019)

Marketed by: Camber Pharmaceuticals

Compared to: Lovaza

Camber Pharmaceuticals has recently been granted approval for omega-3 acid ethyl esters capsules, a generic version of GlaxoSmithKline’s Lovaza. The drug is indicated to lower triglyceride levels and improve HDL cholesterol, or good cholesterol. The generic capsules are available by prescription in 1g doses, and come in 120 count bottles.

For more information: Camberpharma.com

Aspirin-Dipyridamole

Marketed by: Lannett Company

Compared to: Aggrenox

A generic version of Aggrenox has been granted FDA approval for the secondary prevention of stroke in patients who have previously suffered transient ischemic attacks or have clotting disorders. Both aspirin and dipyridamole are antiplatelet drugs that work to keep blood flowing to the brain by preventing clots. Preventing blood clots is crucial, as they can get lodged in the brain and cause strokes.

For more information: Lannett.com

Valsartan

Marketed by: Alkem Laboratories Limited

Compared to: Diovan

The FDA has given a new generic version of valsartan a priority review in an effort to relieve the shortage brought on by a recall. These recalls were implemented after the discovery of nitrosamine impurities in several lots of valsartan and other generic angiotensin II receptor blockers. Valsartan is indicated to treat high blood pressure and heart failure.

For more information: Alkemlabs.com

Imatinib Mesylate Tablets

Marketed by: Breckenridge Pharmaceutical

Compared to: Gleevec

The FDA has recently granted approval to Breckenridge Pharmaceuticals for imatinib mesylate tablets, a tyrosine kinase inhibitor antineoplastic agent used as a chemotherapy for certain cancers, including leukemia. Breckenridge Pharmaceuticals is collaborating with Stason Pharmaceuticals to manufacture the cancer treatment in 100mg and 400mg strength doses.

For more information: BPIrx.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs